Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma.
cancer stem cell markers
glioblastoma
growth data
patient-derived xenografts
preclinical models
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Apr 2020
03 Apr 2020
Historique:
received:
09
03
2020
revised:
27
03
2020
accepted:
01
04
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Glioblastoma is an aggressive brain tumour with a patient median survival of approximately 14 months. The development of innovative treatment strategies to increase the life span and quality of life of patients is hence essential. This requires the use of appropriate glioblastoma models for preclinical testing, which faithfully reflect human cancers. The aim of this study was to establish glioblastoma patient-derived xenografts (PDXs) by heterotopic transplantation of tumour pieces in the axillae of NMRI nude mice. Ten out of 22 patients' samples gave rise to tumours in mice. Their human origin was confirmed by microsatellite analyses, though minor changes were observed. The glioblastoma nature of the PDXs was corroborated by pathological evaluation. Latency times spanned from 48.5 to 370.5 days in the first generation. Growth curve analyses revealed an increase in the growth rate with increasing passages. The methylation status of the
Identifiants
pubmed: 32260145
pii: cancers12040871
doi: 10.3390/cancers12040871
pmc: PMC7226316
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell. 2016 Sep 22;167(1):260-274.e22
pubmed: 27641504
Hum Mol Genet. 2001 Jun 15;10(13):1413-9
pubmed: 11440994
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
J Histochem Cytochem. 2000 Jun;48(6):847-58
pubmed: 10820158
Oncotarget. 2016 Feb 16;7(7):7993-8005
pubmed: 26783960
Neuro Oncol. 2019 May 23;:
pubmed: 31121035
Int J Oncol. 2001 Jun;18(6):1187-93
pubmed: 11351250
J Clin Oncol. 2002 Mar 1;20(5):1375-82
pubmed: 11870182
Neoplasia. 2014 Mar;16(3):193-206, 206.e19-25
pubmed: 24726753
Int J Radiat Oncol Biol Phys. 1992;23(4):803-9
pubmed: 1319979
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Surg Neurol. 2007 Aug;68(2):133-43; discussion 143-4
pubmed: 17537489
Nat Med. 2011 Oct 23;17(11):1514-20
pubmed: 22019887
Oncogene. 2009 Apr 16;28(15):1807-11
pubmed: 19287454
Cancer Res. 2013 Aug 1;73(15):4885-97
pubmed: 23737486
J Transl Med. 2017 Jun 23;15(1):145
pubmed: 28645290
Front Neurol. 2018 Jan 15;8:748
pubmed: 29379468
Cancer Res. 1992 Oct 1;52(19):5334-41
pubmed: 1382841
J Transl Med. 2017 Feb 9;15(1):27
pubmed: 28183348
J Neurosci Methods. 2003 May 30;125(1-2):147-57
pubmed: 12763241
Mol Neurobiol. 2017 Jan;54(1):727-735
pubmed: 26768429
Int J Cancer. 2011 Jan 15;128(2):343-51
pubmed: 20669222
Cancer Chemother Pharmacol. 1989;24(3):148-54
pubmed: 2544306
Cell Rep. 2013 Jan 31;3(1):260-73
pubmed: 23333277
Cancer Res. 2018 Oct 15;78(20):5958-5969
pubmed: 30154149
Oncotarget. 2016 Dec 27;7(52):86406-86419
pubmed: 27863440
Br J Cancer. 2007 Apr 23;96(8):1293-301
pubmed: 17375044
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Clin Cancer Res. 2020 Mar 1;26(5):1094-1104
pubmed: 31852831
Cancer Cell. 2008 Mar;13(3):235-48
pubmed: 18328427
PLoS One. 2016 Jan 05;11(1):e0145100
pubmed: 26731692
Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):99-104
pubmed: 7721644
Clin Cancer Res. 2008 Oct 15;14(20):6456-68
pubmed: 18927285
Radiother Oncol. 2007 Jun;83(3):304-10
pubmed: 17517444
Lab Invest. 2018 Jul;98(7):947-956
pubmed: 29520054
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Nat Genet. 2017 Nov;49(11):1567-1575
pubmed: 28991255
Radiother Oncol. 2012 Mar;102(3):444-9
pubmed: 22100655
Front Surg. 2016 Apr 15;3:21
pubmed: 27148537
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Radiother Oncol. 2014 Dec;113(3):303-9
pubmed: 25458128
Eur J Cancer. 2015 Oct;51(15):2231-2241
pubmed: 26421825
J Biol Chem. 2001 Jun 1;276(22):19052-8
pubmed: 11262404
Cancer Res. 2013 Sep 1;73(17):5315-9
pubmed: 23733750
Drug Resist Updat. 2015 Mar;19:1-12
pubmed: 25791797
Curr Protoc Pharmacol. 2011 Mar;Chapter 14:Unit 14.16
pubmed: 21743824
Nature. 2015 Feb 19;518(7539):422-6
pubmed: 25470049
Cell Death Dis. 2016 Apr 28;7:e2209
pubmed: 27124583
Cancer Res Treat. 2018 Jan;50(1):1-10
pubmed: 28903551
Nat Rev Cancer. 2008 Jul;8(7):545-54
pubmed: 18511937
PLoS One. 2012;7(3):e33449
pubmed: 22428052
J Neurosci. 2015 Nov 11;35(45):15097-112
pubmed: 26558781
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 2004 Oct 1;64(19):7011-21
pubmed: 15466194
Front Oncol. 2017 Jan 19;7:2
pubmed: 28154808
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
Radiat Oncol. 2008 Sep 25;3:32
pubmed: 18817556
J Transl Med. 2013 Aug 27;11:198
pubmed: 23981300
Lab Invest. 2013 Sep;93(9):970-82
pubmed: 23917877
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuro Oncol. 2010 Feb;12(2):116-21
pubmed: 20150378
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046